MINNEAPOLIS, MN, US, Sept. 02, 2021 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets is pleased to announce that Mark Middleton has accepted a position with the Company as its new National Director of Sales.
"With the manufacturing team having successfully implemented commercial manufacture of our initial product, spryng™, our focus on sales has become a key objective to the success of our Company; we believe the vast insight and expertise that Mark possesses puts PetVivo in an excellent position to meet this objective,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Mark is a professional in assembling, coordinating and training a sales force, which can propel the sale of our therapeutic product, spryng with OsteoCushion Technology, for use in companion animals."
Mr. Middleton has more than 38 years of distribution and manufacturing experience in the Animal Health Industry, holding various roles in Sales and Executive Management. As a Division President with Animal Health International (“AHI”), formerly Walco International, he led a team that was instrumental in several company acquisitions, organic growth, and the transition of AHI into a performance-oriented public corporation with revenues of $800 million. In addition to his distribution experience, Mr. Middleton worked as a consultant for FDA manufacturers to develop their markets for both current and new products.
“I am incredibly excited to join PetVivo, a company whose technology has tremendous potential to enhance the lives of companion animals and their owners,” said Mr. Middleton. “I am looking forward to joining a company that possesses disruptive technology, has the ability to grow the market and offers a product that enhances and improves the medical outcomes of animals.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the treatment of osteoarthritis in dogs and horses, is scheduled for expanded commercial sale later this year.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment
